Actively Recruiting

Phase 4
Age: 22Years - 65Years
All Genders
Healthy Volunteers
NCT07210190

Microneedling for Skin Heath

Led by Erevna Innovations Inc. · Updated on 2026-02-05

30

Participants Needed

1

Research Sites

19 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Skin boosters are treatments designed to improve skin quality and restore skin health. Some of these treatments are based on polynucleotides, which are small fragments of DNA. One such compound, called Polydeoxyribonucleotide (PDRN), is obtained from fish sources such as salmon or trout. PDRN has shown regenerative and anti-inflammatory properties, and in medical practice it has been used to support wound healing, scar improvement, and skin rejuvenation by helping with elasticity, texture, and fine lines. VAMP™ Multivitamin Serum is a topical formulation that contains PDRN along with amino acids, vitamins, and peptides. It is designed to improve hydration, elasticity, and overall skin radiance. While early data suggest potential benefits, clinical research is still limited, and further study is needed.

CONDITIONS

Official Title

Microneedling for Skin Heath

Who Can Participate

Age: 22Years - 65Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand study information and provide signed informed consent
  • Interest in improving skin quality
  • Immune-competent adults aged 22 years and older
  • Intent to undergo treatment to improve facial skin appearance
  • Willingness to comply with pre-visit instructions including facial shaving for males
  • Females of childbearing potential must agree to use effective contraception during the study and take urine pregnancy tests at baseline and before treatments
  • Negative urine pregnancy test for women of childbearing potential at baseline
  • Stable lifestyle and skincare routine for at least 4 weeks
Not Eligible

You will not qualify if you...

  • Allergy or sensitivity to components of VAMP17 Advanced Topical Multivitamin Serum, including sodium hyaluronate, peptides, polynucleotides (e.g., PDRN), or excipients
  • Allergy or intolerance to topical anesthetics or lidocaine
  • History of severe allergic reactions such as anaphylaxis or angioedema
  • History of hypertrophic scarring, keloid formation, or post-inflammatory hyperpigmentation after cosmetic treatments
  • Tattoos, piercings, or skin bleaching in the treatment area that interfere with assessments
  • Known pigmentary instability or adverse response to microneedling
  • Recent cosmetic or dermatologic procedures in treatment area within specified time frames
  • Use of topical corticosteroids, retinoids, or depigmenting agents in treatment area within past 4 weeks
  • Current immunosuppressive therapy, systemic corticosteroids, or chemotherapy within last 3 months
  • History of systemic autoimmune, collagen vascular, or bleeding disorders
  • Current pregnancy, breastfeeding, or intent to become pregnant during study
  • Participation in another clinical trial within past 30 days
  • Conditions interfering with consent or protocol compliance
  • Recent weight loss program or GLP-1 agonist therapy initiation
  • Active skin conditions worsened by microneedling
  • Study personnel or immediate family participation
  • Known allergy to fish or seafood
  • History of cancer or radiation near treatment area
  • Heavy smoking (>12 cigarettes/day)
  • Presence of disease or lesions near treatment area such as inflammation, infection, psoriasis, eczema, cancer, severe skin laxity, advanced photoaged skin
  • Skin coloring, bleaching, or tattoos in treatment area interfering with assessments
  • Underlying diseases or conditions increasing risk
  • Use of medications affecting bleeding within 14 days prior to injection
  • Recent chemotherapy, immunosuppressive agents, or systemic corticosteroids treatment
  • Unstable hormonal therapy
  • Recent use or planned use of certain topical or systemic retinoids
  • Pregnancy or breastfeeding during study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Erevna Innovations Inc.

Montreal, Quebec, Canada, H3Z 1C3

Actively Recruiting

Loading map...

Research Team

L

Laura Raco

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here